A Comparison of the Appraisals by the English National Institute for Health and Care Excellence (NICE) for Two Therapies for Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL): Idelalisib+Rituximab (IR) and Ibrutinib

Value in Health- United Kingdom

doi 10.1016/j.jval.2017.08.407

Full Text

Abstract

Available in

Date

Authors

Publisher

Elsevier BV

Related search

Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Utility Values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Analysis of Treatment Options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Cost-Utility of Idelalisib in Combination With Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Php295 - Review of Possible Causes of Variation in National Institute for Health and Care Excellence (Nice) Technology Appraisals

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Breakthrough Therapy in Relapsed Chronic Lymphocytic Leukemia: The Combination of Idelalisib and Rituximab

Postdoc journal
2014English

Comparative Analysis of Targeted Novel Therapies in Relapsed, Refractory Chronic Lymphocytic Leukaemia

Haematologica
Hematology
2020English

Comparison of Innate Immunity Changes Following Ibrutinib and Venetoclax Treatment of Relapsed Chronic Lymphocytic Leukaemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy